TW202003001A - 包含細菌菌株之組成物 - Google Patents

包含細菌菌株之組成物 Download PDF

Info

Publication number
TW202003001A
TW202003001A TW108109417A TW108109417A TW202003001A TW 202003001 A TW202003001 A TW 202003001A TW 108109417 A TW108109417 A TW 108109417A TW 108109417 A TW108109417 A TW 108109417A TW 202003001 A TW202003001 A TW 202003001A
Authority
TW
Taiwan
Prior art keywords
composition
present
cells
seq
bacterial strain
Prior art date
Application number
TW108109417A
Other languages
English (en)
Chinese (zh)
Inventor
多蒙尼克 潘辛卡
艾咪 貝絲 赫特
蘇艾德 亞曼德
安娜 艾托爾
映姆科 伊莉莎白 慕得
菲力浦 科威
艾瑪 拉法蒂斯
艾瑪 伊莉莎白 克萊爾 軒尼詩
達芬 路易斯 克勞黛 卡利
梅納 歐黑莉 帕斯卡 派翠西亞 庫特里爾
印克斯特 瑪格麗特 迪爾戴
馬斯里歐 亞德里安尼
瑪莉亞 克里斯托夫
Original Assignee
英商4D製藥研究有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1804384.4A external-priority patent/GB201804384D0/en
Priority claimed from GBGB1809953.1A external-priority patent/GB201809953D0/en
Priority claimed from GBGB1811900.8A external-priority patent/GB201811900D0/en
Priority claimed from GBGB1812378.6A external-priority patent/GB201812378D0/en
Priority claimed from GBGB1813444.5A external-priority patent/GB201813444D0/en
Priority claimed from GBGB1813423.9A external-priority patent/GB201813423D0/en
Priority claimed from GBGB1816834.4A external-priority patent/GB201816834D0/en
Priority claimed from GBGB1817641.2A external-priority patent/GB201817641D0/en
Priority claimed from GBGB1901218.6A external-priority patent/GB201901218D0/en
Priority claimed from GBGB1901199.8A external-priority patent/GB201901199D0/en
Priority claimed from GBGB1901992.6A external-priority patent/GB201901992D0/en
Priority claimed from GBGB1901993.4A external-priority patent/GB201901993D0/en
Application filed by 英商4D製藥研究有限公司 filed Critical 英商4D製藥研究有限公司
Publication of TW202003001A publication Critical patent/TW202003001A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Rheumatology (AREA)
TW108109417A 2018-03-19 2019-03-19 包含細菌菌株之組成物 TW202003001A (zh)

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
GBGB1804384.4A GB201804384D0 (en) 2018-03-19 2018-03-19 Compositions
GB1804384.4 2018-03-19
EP18178350 2018-06-18
GBGB1809953.1A GB201809953D0 (en) 2018-06-18 2018-06-18 Compositions
EP18178350.7 2018-06-18
GB1809953.1 2018-06-18
GBGB1811900.8A GB201811900D0 (en) 2018-07-20 2018-07-20 Compositions comprising bacterial strains
GB1811900.8 2018-07-20
GBGB1812378.6A GB201812378D0 (en) 2018-07-30 2018-07-30 Compositions comprising bacterial strains
GB1812378.6 2018-07-30
GBGB1813444.5A GB201813444D0 (en) 2018-08-17 2018-08-17 Compositions
GBGB1813423.9A GB201813423D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GB1813423.9 2018-08-17
GB1813444.5 2018-08-17
GBGB1816834.4A GB201816834D0 (en) 2018-10-16 2018-10-16 Compositions
GB1816834.4 2018-10-16
GB1817641.2 2018-10-29
GBGB1817641.2A GB201817641D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GB1901199.8 2019-01-29
GBGB1901218.6A GB201901218D0 (en) 2019-01-29 2019-01-29 Compositions
GBGB1901199.8A GB201901199D0 (en) 2019-01-29 2019-01-29 Compositions comprising bacterial strains
GB1901218.6 2019-01-29
GB1901993.4 2019-02-13
GBGB1901992.6A GB201901992D0 (en) 2019-02-13 2019-02-13 Compositions comprising bacterial strains
GBGB1901993.4A GB201901993D0 (en) 2019-02-13 2019-02-13 Compositions
GB1901992.6 2019-02-13

Publications (1)

Publication Number Publication Date
TW202003001A true TW202003001A (zh) 2020-01-16

Family

ID=65955185

Family Applications (2)

Application Number Title Priority Date Filing Date
TW108109417A TW202003001A (zh) 2018-03-19 2019-03-19 包含細菌菌株之組成物
TW108109387A TW202003000A (zh) 2018-03-19 2019-03-19 組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108109387A TW202003000A (zh) 2018-03-19 2019-03-19 組成物

Country Status (25)

Country Link
US (3) US11419931B2 (enExample)
EP (3) EP4046644A1 (enExample)
JP (3) JP2021518414A (enExample)
KR (2) KR102578117B1 (enExample)
CN (2) CN112004543A (enExample)
AU (2) AU2019239048B2 (enExample)
BR (2) BR112020019008A2 (enExample)
CA (2) CA3094297A1 (enExample)
CY (1) CY1125104T1 (enExample)
DK (1) DK3768284T3 (enExample)
ES (1) ES2908826T3 (enExample)
HR (1) HRP20220368T1 (enExample)
HU (1) HUE058151T2 (enExample)
IL (2) IL277422A (enExample)
LT (1) LT3768284T (enExample)
MA (1) MA52128A (enExample)
MD (1) MD3768284T2 (enExample)
MX (2) MX2020009733A (enExample)
PL (1) PL3768284T3 (enExample)
RS (1) RS63090B1 (enExample)
SG (2) SG11202009254YA (enExample)
SI (1) SI3768284T1 (enExample)
SM (1) SMT202200111T1 (enExample)
TW (2) TW202003001A (enExample)
WO (2) WO2019180051A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021113500A2 (en) * 2019-12-03 2021-06-10 Board Of Regents, The University Of Texas System Combination therapies for the treatment of cancer
EP4161541A4 (en) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS
KR102461645B1 (ko) * 2020-10-20 2022-11-01 전남대학교산학협력단 플라젤린 융합 단백질을 포함하는 비알코올성 지방간질환 또는 대사증후군 예방 또는 치료용 조성물
EP4384194A4 (en) * 2021-10-08 2025-07-16 Univ Iowa State Res Found Inc USE OF DOPAMINE-PRODUCING PRODUCTS TO INCREASE VACCINE EFFECTIVENESS
CN113999923B (zh) * 2021-11-25 2024-05-14 上海金翌生物科技有限公司 小柳-原田综合症标志微生物及其应用
CN115287243B (zh) * 2022-04-15 2023-06-06 集美大学 一株变形假单胞菌flgK基因沉默菌株及其构建方法
JPWO2024096122A1 (enExample) * 2022-11-04 2024-05-10
KR102878250B1 (ko) 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20080025977A1 (en) 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
EP1958647A1 (en) 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
EP2133092B1 (en) 2007-03-19 2015-12-09 Morishita Jintan Co., Ltd. Oral vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
EP2486134B1 (en) * 2009-10-06 2014-01-08 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP2663367A4 (en) 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
EP2731572B1 (en) 2011-07-13 2021-04-07 Pharmaxis Ltd. Improvements relating to delivery devices
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
FR2989002B1 (fr) 2012-04-10 2015-05-15 Beepratte Lab Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique
WO2014043593A2 (en) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10480002B2 (en) * 2014-02-12 2019-11-19 Transalgae Israel Ltd. Algal based edible vaccines
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41013A (fr) * 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520502D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41708A (fr) * 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
BR112020002212A2 (pt) 2017-08-10 2020-07-28 4D Pharma Research Limited composições compreendendo cepas bacterianas
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains

Also Published As

Publication number Publication date
US20210138058A1 (en) 2021-05-13
EP3768285A1 (en) 2021-01-27
JP2021518414A (ja) 2021-08-02
RS63090B1 (sr) 2022-04-29
JP2023100747A (ja) 2023-07-19
US20210169950A1 (en) 2021-06-10
JP2021518129A (ja) 2021-08-02
WO2019180000A1 (en) 2019-09-26
MA52128A (fr) 2021-01-27
SG11202009254YA (en) 2020-10-29
WO2019180051A1 (en) 2019-09-26
PL3768284T3 (pl) 2022-04-11
AU2019239048A1 (en) 2020-11-05
AU2019239048B2 (en) 2022-07-21
SMT202200111T1 (it) 2022-05-12
CY1125104T1 (el) 2024-02-16
ES2908826T3 (es) 2022-05-04
IL277421A (en) 2020-11-30
CN111886018A (zh) 2020-11-03
MX2020009733A (es) 2022-10-27
IL277421B (en) 2022-04-01
MD3768284T2 (ro) 2022-06-30
US11419931B2 (en) 2022-08-23
EP4046644A1 (en) 2022-08-24
CA3094297A1 (en) 2019-09-26
EP3768284B1 (en) 2022-01-05
SI3768284T1 (sl) 2022-04-29
DK3768284T3 (da) 2022-03-07
CA3094139A1 (en) 2019-09-26
BR112020019008A2 (pt) 2020-12-29
AU2019238358A1 (en) 2020-10-08
US11857614B2 (en) 2024-01-02
MX2020009736A (es) 2021-01-08
TW202003000A (zh) 2020-01-16
SG11202009259VA (en) 2020-10-29
US20220257745A1 (en) 2022-08-18
HUE058151T2 (hu) 2022-07-28
KR102578117B1 (ko) 2023-09-12
CN112004543A (zh) 2020-11-27
BR112020018818A2 (pt) 2021-05-04
KR20210003096A (ko) 2021-01-11
HRP20220368T1 (hr) 2022-06-24
LT3768284T (lt) 2022-04-11
EP3768284A1 (en) 2021-01-27
IL277422A (en) 2020-11-30
KR20200134255A (ko) 2020-12-01

Similar Documents

Publication Publication Date Title
US11419931B2 (en) Compositions comprising bacterial strains
US11058732B2 (en) Compositions comprising bacterial strains
TW201922270A (zh) 使用免疫調節乳球菌屬 (lactococcus) 細菌菌株治療免疫病症之組合物及方法
US20230048366A1 (en) Combination therapy for treating or preventing cancer
US20230277602A1 (en) Combination therapy for treating or preventing cancer
US20210330786A1 (en) Compositions comprising bacterial strains
WO2019141999A1 (en) Combination therapy for treating or preventing cancer
JP2021510688A (ja) がんを処置または予防するための併用療法
OA20782A (en) Compositions comprising bacterial strains.
US20210393773A1 (en) Compositions comprising bacterial strains
OA20162A (en) Combination therapy for treating or preventing cancer
OA20494A (en) Compositions comprising bacterial strains
Geis REGULATORY T CELLS PROMOTE IL-17-DEPENDENT CARCINOGENIC IMMUNITY TO ENTEROTOXIGENIC BACTEROIDES FRAGILIS
OA20165A (en) Combination therapy for treating or preventing cancer.
Lemire et al. Differential modulation of natural killer cell functions during the innate immune response to pathogenic streptococci